Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
Damien Giacchero, V. Sibaud, E. Gérard, Célèste Lebbé, Jesse Hirner, Olivier Gaide, Vasiliki Nikolaou, Pietro Sollena, Chryssa Oikonomou, Emma Huard, Thierry Passeron, Johana Rousset, Michela Starace, Francesca Bruni, Priscila Giavedoni, Azael Freites‐Martínez, Davide Fattore, Ana Clara Torre, Alicia Jiménez Antón, Cristina Carrera, Dimitra Koumaki, Florentina Delli, Yannick S. Elshot, Julia Riganti, Lukas Kraehenbuehl, Konstantinos Lallas, Zoé Apalla
Abstract
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
MedicineDupilumabImmunologyImmune systemImmunotherapyDermatologyAntibodyMEDLINEImmunopathologyNivolumabMonoclonalImmune checkpointCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways